A5012025332- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Prostate Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Peptidase Inhibition and Analysis
- Advanced Radiotherapy Techniques
- Urologic and reproductive health conditions
- Advanced X-ray and CT Imaging
- Mass Spectrometry Techniques and Applications
- Hormonal and reproductive studies
- Medical Image Segmentation Techniques
- Lung Cancer Treatments and Mutations
- Medical Imaging and Analysis
- Advanced Neural Network Applications
- Artificial Intelligence in Healthcare and Education
- Radiation Therapy and Dosimetry
- Bone health and treatments
- Renal cell carcinoma treatment
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Autopsy Techniques and Outcomes
- Boron Compounds in Chemistry
- Cancer Immunotherapy and Biomarkers
Johns Hopkins Medicine
2023-2025
Johns Hopkins University
2023-2025
Molecular Theranostics (United States)
2021-2025
Johns Hopkins Hospital
2024-2025
Klinikum rechts der Isar
2018-2025
Technical University of Munich
2018-2024
University of California, Los Angeles
2020-2024
UCLA Health
2020-2024
LMU Klinikum
2023
Ludwig-Maximilians-Universität München
2023
<sup>18</sup>F-labeled prostate-specific membrane antigen (PSMA)–ligand PET has several principal advantages over <sup>68</sup>Ga-PSMA-11. The purpose of this retrospective study was to evaluate the frequency non–tumor-related uptake and detection efficacy comparing <sup>68</sup>Ga-PSMA-11 PET/CT <sup>18</sup>F-PSMA-1007 in recurrent prostate cancer (PC) patients. <b>Methods:</b> included 102 patients with biochemically PC after radical prostatectomy undergoing imaging. On basis various...
BackgroundLutetium-177 (177Lu) prostate-specific membrane antigen (177Lu-PSMA) is a novel targeted treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). Predictors of outcomes after 177Lu-PSMA to enhance its clinical implementation are yet be identified. We aimed develop nomograms predict in mCRPC.MethodsIn this multicentre, retrospective study, we screened mCRPC who had received between Dec 10, 2014, and July 19, 2019, as part the previous phase 2 trials...
Our objective was to develop version 1.0 of a novel framework for response evaluation criteria in prostate-specific membrane antigen (PSMA) PET/CT (RECIP) and composite classification that combines responses by (PSA) measurements RECIP (PSA + RECIP). Methods: This an international multicenter, retrospective study. One hundred twenty-four men with metastatic castration-specific prostate cancer (mCRPC) who underwent 177Lu-PSMA therapy received PSMA at baseline interim time point 12 wk were...
Background Response Evaluation Criteria in Prostate-specific Membrane Antigen (PSMA) PET/CT (RECIP 1.0) initially integrated software-based quantitative assessment of PSMA-positive total tumor volume (TTV). Clinical implementation such software is not expected soon, limiting the use RECIP practice. Purpose To assess agreement determined using segmentation (quantitative RECIP) with by qualitative reads nuclear medicine physicians (visual for response evaluation metastatic castration-resistant...
Our aim was to introduce and validate qPSMA, a semiautomatic software package for whole-body tumor burden assessment in prostate cancer patients using 68Ga-prostate-specific membrane antigen (PSMA) 11 PET/CT. Methods: qPSMA reads hybrid PET/CT images DICOM format. Its pipeline written Python C++ languages. A bone mask based on CT normal-uptake including organs with physiologic 68Ga-PSMA11 uptake are automatically computed. An SUV threshold of 3 liver-based used segment soft-tissue lesions,...
To evaluate the performance of combined PET and multiparametric MRI (mpMRI) radiomics for group-wise prediction postsurgical Gleason scores (psGSs) in primary prostate cancer (PCa) patients. Patients with PCa, who underwent [68 Ga]Ga-PSMA-11 PET/MRI followed by radical prostatectomy, were included this retrospective analysis (n = 101). grouped psGS three categories: ISUP grades 1-3, grade 4, 5. mpMRI images T1-weighted, T2-weighted, apparent diffusion coefficient (ADC) map. Whole-prostate...
We aimed to systematically determine the impact of tumor burden on
The aim of the study was to assess outcome patients with metastatic castration-resistant prostate cancer treated <sup>177</sup>Lu-prostate-specific membrane antigen (PSMA) who would have been a screen failure (SF) in VISION trial based on PSMA PET/CT criteria. <b>Methods:</b> We conducted retrospective multicenter cohort 301 <sup>177</sup>Lu-PSMA. were classified into eligible (VISION-PET-E) and SF (VISION-PET-SF) groups basis baseline results. Prostate-specific (PSA) response rates, PSA...
Prostate-specific Membrane Antigen Reporting and Data System (PSMA-RADS) was introduced for standardized reporting, PSMA-RADS version 1.0 allows classification of lesions based on their likelihood representing a site prostate cancer PSMA-targeted positron emission tomography (PET). In recent years, this system has extensively been investigated. Increasing evidence accumulated that the different categories reflect actual meanings, such as true positivity in 4 5 lesions. Interobserver...
Prostate-specific membrane antigen (PSMA)–targeted radioligand therapy can improve the outcome of patients with advanced metastatic castration-resistant prostate cancer, but do not respond uniformly. We hypothesized that using salivary glands as a reference organ enable selective patient stratification. aimed to establish PSMA PET tumor–to–salivary gland ratio (PSG score) predict outcomes after [<sup>177</sup>Lu]PSMA. <b>Methods:</b> In total, 237 men cancer treated [<sup>177</sup>Lu]PSMA...
Our aim was to assess the diagnostic potential of 1-stop-shop prostate-specific membrane antigen ligand (<sup>68</sup>Ga-PSMA-11) PET/MRI compared with preoperative staging nomograms in patients high-risk prostate cancer. <b>Methods:</b> A total 102 underwent <sup>68</sup>Ga-PSMA-11 before intended radical prostatectomy lymph node dissection. Preoperative variables determined probabilities for metastases (LNM), extracapsular extension (ECE), and seminal vesical involvement (SVI) using...
PURPOSE Image analysis is one of the most promising applications artificial intelligence (AI) in health care, potentially improving prediction, diagnosis, and treatment diseases. Although scientific advances this area critically depend on accessibility large-volume high-quality data, sharing data between institutions faces various ethical legal constraints as well organizational technical obstacles. METHODS The Joint Imaging Platform (JIP) German Cancer Consortium (DKTK) addresses these...
PSMA is a transmembrane protein that markedly overexpressed in prostate cancer, making it an excellent target for imaging and treating patients with cancer. Several small molecule inhibitors antibodies of have been radiolabeled use as therapeutic agents are currently under clinical investigation. PSMA-based radionuclide therapy promising option men metastatic The phase II TheraP study demonstrated superior efficacy, lower side effects, improved patient-reported outcomes compared cabazitaxel....
<sup>177</sup>Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy effectively treats metastatic castration-resistant prostate cancer. Patients requiring treatment, and consequently the number of theranostic centers, are expected to increase significantly after Food Drug Administration European Medicines Agency approval. This requires standardization or harmonization among centers. The aim this study was assess operational differences similarities <sup>177</sup>Lu-PSMA...
Prostate-specific antigen (PSA) is widely used to monitor treatment response in patients with metastatic castration-resistant prostate cancer. However, PSA measurements are considered only after 12 wk of treatment. We aimed evaluate the prognostic value early changes <sup>177</sup>Lu-labeled prostate-specific membrane (<sup>177</sup>Lu-PSMA) radionuclide cancer patients. <b>Methods:</b> Men who were treated <sup>177</sup>Lu-PSMA under a compassionate-access program at our institution and had...
The objective of this study was to determine prospectively the efficacy profile 2 activity regimens <sup>177</sup>Lu-PSMA therapy in patients with progressive metastatic castrate-resistant prostate cancer (mCRPC): 6.0 vs. 7.4 GBq. <b>Methods:</b> RESIST-PC (NCT03042312) a prospective multicenter phase trial. Patients mCRPC after ≥ 1 novel androgen-axis drug, either chemotherapy naïve or postchemotherapy, sufficient bone marrow reserve, normal kidney function, and PSMA expression by PET were...
In PSMA-ligand PET/CT imaging, standardized evaluation frameworks and image-derived parameters are increasingly used to support prostate cancer staging. Clinical applicability remains challenging wherever manual measurements of numerous suspected lesions required. Deep learning methods promising for automated image analysis, typically requiring extensive expert-annotated datasets reach sufficient accuracy. We developed a deep method image-based staging, investigating the use training...
Although treatment planning and individualized dose application for emerging prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) are generally recommended, it is still difficult to implement in practice at the moment. In this study, we aimed prove concept of pretherapeutic prediction dosimetry based on imaging laboratory measurements before RLT treatment.